Ongoing Disclosure Notices – Options & PSRs

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
13 September 2023
Date of last disclosure:
21 March 2023
Director or senior manager giving disclosure
Full name(s):
Andrew Robert Donald Somervell
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Vice President - Products & Technology
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
(a) Options to acquire Ordinary Shares
(b) Performance Share Rights
Nature of the affected relevant interest(s):
Beneficial
For that relevant interest
Number held in class before acquisition or disposal:
a) 117,884 Options
b) 42,851 Performance Share Rights
Number held in class after acquisition or disposal:
(a) 154,649 Options
(b) 58,850 Performance Share Rights
Current registered holder(s):
Andrew Robert Donald Somervell
Registered holder(s) once transfers are registered:
Andrew Robert Donald Somervell
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under
the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Two
Details of transactions requiring disclosure-
Date of transaction:
(a) 12 September 2023
(b) 12 September 2023
Nature of transaction:
(a) Issue of Options
(b) Issue of Performance Share Rights
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily converted into a
cash value, describe the consideration:
(a) $nil
(b) $nil

Number of financial products to which the transaction related:
(a) 36,765 Options
(b) 15,999 Performance Share Rights
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the aquisition or disposal to proceed
during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Ordinary Shares
Nature of relevant interest:
Beneficial
For that relevant interest,-
Number held in class:
98,631
Current registered holder(s):
Andrew Somervell
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under
the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons for
whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:13 September 2023
Name and title of authorised person:Raelene Leonard, Company Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
13 September 2023
Date of last disclosure:
27 September 2022
Director or senior manager giving disclosure
Full name(s):
Lewis George Gradon
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Executive Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
(a) Options to acquire Ordinary Shares
(b) Performance Share Rights
Nature of the affected relevant interest(s):
Beneficial
For that relevant interest:
Number held in class before acquisition or disposal:
(a) 411,162 Options
(b) 148,536 Performance Share Rights
Number held in class after acquisition or disposal:
(a) 524,339 Options
(b) 197,786 Performance Share Rights
Current registered holder(s):
Lewis George Gradon
Registered holder(s) once transfers are registered:
Lewis George Gradon
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative:
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative:
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure:
Date of transaction:
(a) 12 September 2023
(b) 12 September 2023
Nature of transaction:
(a) Issue of Options
(b) Issue of Performance Share Rights
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily converted into a
cash value, describe the consideration:
(a) $nil
(b) $nil

Number of financial products to which the transaction related:
(a) 113,177 Options
(b) 49,250 Performance Share Rights
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details:
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal
Class of quoted financial products:
Ordinary Shares
Nature of relevant interest:Beneficial
For that relevant interest:
Number held in class:
562,351
Current registered holder(s):Lewis George Gradon; Gradon Family Trust
For a derivative relevant interest:
Type of derivative:
Details of derivative:
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest:
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:13 September 2023
Name and title of authorised person:Raelene Leonard, Company Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
13 September 2023
Date of last disclosure:
21 July 2023
Director or senior manager giving disclosure
Full name(s):
Lyndal Jane York
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Financial Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
(a) Options to acquire Ordinary Shares
(b) Performance Share Rights
Nature of the affected relevant interest(s):
Beneficial
For that relevant interest
Number held in class before acquisition or disposal:
(a) 132,016 Options
(b) 50,237 Performance Share Rights
Number held in class after acquisition or disposal:
(a) 189,624 Options
(b) 75,306 Performance Share Rights
Current registered holder(s):
Lyndal Jane York
Registered holder(s) once transfers are registered:
Lyndal Jane York
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Two
Details of transactions requiring disclosure-
Date of transaction:
(a) 12 September 2023
(b) 12 September 2023
Nature of transaction:
(a) Issue of Options
(b) Issue of Performance Share Rights
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
(a) $nil
(b) $nil

Number of financial products to which the transaction related:
(a) 57,608 Options
(b) 25,069 Performance Share Rights
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the aquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Ordinary Shares
Nature of relevant interest:
Beneficial
For that relevant interest,-
Number held in class:
1060
Current registered holder(s):
Lyndal Jane York & Alexander Eric York
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:13 September 2023
Name and title of authorised person:Raelene Leonard, Company Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
13 September 2023
Date of last disclosure:
10 February 2023
Director or senior manager giving disclosure
Full name(s):Paul Nigel Shearer
Name of listed issuer:Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Vice President - Sales & Marketing
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
(a) Options to acquire Ordinary Shares
(b) Performance Share Rights
Nature of the affected relevant interest(s):
Beneficial
For that relevant interest-
Number held in class before acquisition or disposal:
(a) 201,698 Options
(b) 73,136 Performance Share Rights
Number held in class after acquisition or disposal:
(a) 260,522 Options
(b) 98,734 Performance Share Rights
Current registered holder(s):Paul Nigel Shearer
Registered holder(s) once transfers are registered:Paul Nigel Shearer
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Two
Details of transactions requiring disclosure-
Date of transaction:
(a) 12 September 2023
(b) 12 September 2023
Nature of transaction:
(a) Issue of Options
(b) Issue of Performance Share Rights
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or recieved for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
(a) $nil
(b) $nil

Number of financial products to which the transaction related:
(a) 58,824 Options
(b) 25,598 Performance Share Rights
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the aquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Ordinary Shares
Nature of relevant interest:
Beneficial
For that relevant interest,-
Number held in class:
384,968
Current registered holder(s):
Paul Nigel Shearer, Shearer Family Trust
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:13 September 2023
Name and title of authorised person:Raelene Leonard, Company Secretary